Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

What is required to advance data ethics, data sharing, and Open Science across LMICs

Dr Priya Kumari - Regional Cancer Centre Trivandrum, Trivandrum, India
What is required to advance data ethics, data sharing, and Open Science across LMICs ( Dr Priya Kumari - Regional Cancer Centre Trivandrum, Trivandrum, India )
20 Dec 2022

A genomic assay may predict long-term prognosis in premenopausal patients with HR+ early-stage breast cancer

Dr Ruth O'Regan - University of Rochester, Rochester, USA
A genomic assay may predict long-term prognosis in premenopausal patients with HR+ early-stage breast cancer ( Dr Ruth O'Regan - University of Rochester, Rochester, USA )
19 Dec 2022

Camizestrant may be superior to fulvestrant in patients with hormone receptor-positive, HER2-negative breast cancer

Dr Mafalda Oliveira - Vall d’Hebron University Hospital, Barcelona, Spain
Camizestrant may be superior to fulvestrant in patients with hormone receptor-positive, HER2-negative breast cancer ( Dr Mafalda Oliveira - Vall d’Hebron University Hospital, Barcelona, Spain )
14 Dec 2022

Treatment decision guided by CTC count may improve long-term outcomes for mBC

Prof Jean-Yves Pierga - Institut Curie, Paris, France
Treatment decision guided by CTC count may improve long-term outcomes for mBC ( Prof Jean-Yves Pierga - Institut Curie, Paris, France )
9 Dec 2022

Access to Oncology Medicines Coalition - The Medicines Patent Pool

Charles Gore - Medicines Patent Pool, Geneva, Switzerland
Access to Oncology Medicines Coalition - The Medicines Patent Pool ( Charles Gore - Medicines Patent Pool, Geneva, Switzerland )
1 Dec 2022

Final OS analysis of ICARIA-MM: Isatuximab triplet shows continued survival benefit in R/R multiple myeloma

Dr Paul Richardson - Dana Farber Cancer Institue, Boston, USA
Final OS analysis of ICARIA-MM: Isatuximab triplet shows continued survival benefit in R/R multiple myeloma ( Dr Paul Richardson - Dana Farber Cancer Institue, Boston, USA )
12 Oct 2022

Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for unresected LA SCCHN

Prof Jean Bourhis - University Hospital of Lausanne, Lausanne, Switzerland
Xevinapant plus standard of care chemoradiotherapy improved 5 year OS for unresected LA SCCHN ( Prof Jean Bourhis - University Hospital of Lausanne, Lausanne, Switzerland )
27 Sep 2022

Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced breast cancer

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA
Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )
21 Sep 2022

ESMO 2022: Breast and ovarian trial analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2022: Breast and ovarian trial analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
14 Sep 2022

ERMES study suggests a strategy of de-escalation with only cetuximab in first line therapy for RAS and BRAF wild type mCRC

Dr Armando Orlandi - Agostino Gemelli University Polyclinic, Rome, Italy
ERMES study suggests a strategy of de-escalation with only cetuximab in first line therapy for RAS and BRAF wild type mCRC ( Dr Armando Orlandi - Agostino Gemelli University Polyclinic, Rome, Italy )
14 Sep 2022

Neoadjuvant immunotherapy improves outlook in high-risk melanoma

Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA
Neoadjuvant immunotherapy improves outlook in high-risk melanoma ( Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA )
14 Sep 2022

Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial cancer

Prof Jonathan E Rosenberg - Memorial Sloan Kettering Cancer Center, New York City, USA
Potential for enfortumab vedotin plus pembrolizumab in cisplatin-ineligible locally advanced or metastatic urothelial cancer ( Prof Jonathan E Rosenberg - Memorial Sloan Kettering Cancer Center, New York City, USA )
14 Sep 2022